ReleaseWire Connect

DynaCERT Inc. (OTCQX:DYFSF) ("dynaCERT" or the "Company") announced that it will reopen its offices and newly updated Assembly Plant in Toronto (Canada) after the long four and a half month (4-1/2) hiatus imposed under the general Government of Ontario restrictions as a result of the COVID-19 pandemic.

SinglePoint Inc., (OTCQB:SING) released a statement that Direct Solar of America, LLC ("Direct Solar"), its majority-owned subsidiary, is entering into a ("LOI") Letter of Intent to acquire the entire Standard Eco Solar, an installer and developer of grid-tied solar electric systems in Arizona, Texas, and Illinois for a combination of stock and cash. SinglePoint and Direct Solar are currently doing due diligence, and SinglePoint is expected to issue common stock immediately the audit and definitive agreements are finalized, facilitating this investment via Direct Solar of America. It is anticipated that the transaction will close the latest by December 2020. In 2018, Standard Eco Solar realized unaudited revenues of 12,331,701 USD, and in 2019, their unaudited revenues stood at 11,345,061 USD. It was operationally profitable in 2018 and 2019.

SinglePoint Inc. (OTCQB:SING) ("SinglePoint"), announced that its majority owned subsidiary, Direct Solar of America, LLC ("Direct Solar"), has entered into a Letter of Intent ("LOI") to acquire Standard Eco Solar ("Standard Eco"), a developer and installer of grid-tied solar electric systems in Texas, Illinois, and Arizona for a combination of cash and stock. Direct Solar and SinglePoint are currently conducting due diligence and SinglePoint will issue common stock once the definitive agreement and audit are completed, facilitating this investment through Direct Solar of America. The transaction is expected to close no later than December 2020. Standard Eco achieved unaudited revenues of $12,331,703 in 2018 and $11,345,061 in 2019 and was operationally profitable in both years.

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, announced that the Company, together with partner OntoChem GmbH, has synthesized four potential Covid-19 compounds that will advance to biological assay testing. Anixa and OntoChem announced their partnership on April 20, 2020 and announced discovery of its first potential Covid-19 candidate two weeks later on May 4, 2020.

While Anixa Biosciences (NASDAQ:ANIX) has gained some visibility for their recent work on Covid-19, it's important to understand that that company has some additional compelling assets. Today, I want to discuss their breast cancer vaccine program. I wont discuss all the market size details about breast cancer as most of us know that breast cancer is the most common cancer diagnosed in women in the US and throughout the world. The most dangerous type of breast cancer is something called, triple negative breast cancer (TNBC). It is called TNBC because the cancer is negative for hormone receptors as well as Her2neu, a marker for a type of breast cancer. Because it does not have those receptors, TNBC grows rapidly without growth signals provided by the proteins that bind to those receptors. Roughly on quarter of all breast cancers are TNBC, but because of its aggressiveness and lack of good therapies for TNBC, it is the cause of roughly half of breast cancer mortality.

Anixa with partner OntoChem GmbH, has identified its first therapeutic candidate against Covid-19, and has advanced the compound into biological testing.

Anixa Biosciences and OntoChem Recently Announced The Discovery of First Covid-19 Therapeutic Candidate

Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, announced that it, with partner OntoChem GmbH, has identified its first therapeutic candidate against Covid-19, and has advanced the compound into biological testing.

Full Interview With CEO Dr. David Jin

The clinical trial will interrogate the treatment of relapsed/refractory B-cell malignancies, including B-cell lymphoblastic leukemia (B-ALL) and non-Hodgkin's Lymphoma (NHL)